Cargando…
Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype.
CA19-9, a serum marker for pancreatic cancer, gives false-negative results in patients who are negative for the Lewis blood group phenotype. To determine whether other markers may compensate for this drawback, serum levels of CA50, Span-1, sialyl SSEA-1 and Dupan-2 were assayed and compared with tho...
Autores principales: | Kawa, S., Oguchi, H., Kobayashi, T., Tokoo, M., Furuta, S., Kanai, M., Homma, T. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977472/ https://www.ncbi.nlm.nih.gov/pubmed/1931612 |
Ejemplares similares
-
Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
por: Kawa, S., et al.
Publicado: (1994) -
An evaluation of DUPAN-2 in pancreatic cancer and gastrointestinal disease.
por: Cooper, E. H., et al.
Publicado: (1990) -
Comparative study of CA242 and CA19-9 in chronic pancreatitis.
por: Furuya, N., et al.
Publicado: (1996) -
DUPAN-II normalisation as a biological indicator during preoperative chemoradiation therapy for resectable and borderline resectable pancreatic cancer
por: Hasegawa, Shinichiro, et al.
Publicado: (2023) -
Autoimmune pancreatitis can develop into chronic pancreatitis
por: Maruyama, Masahiro, et al.
Publicado: (2014)